New drug duo aims to make inoperable sinus cancer removable
NCT ID NCT07522879
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted antibody-drug conjugate) and epirubicin (a standard chemo)—in 40 people with EGFR-positive, recurrent sinonasal adenoid cystic carcinoma that cannot be surgically removed. The goal is to shrink the tumor enough to allow radical surgery. The study measures how many patients respond and whether they can then undergo successful tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug vedotin (MRG003) combined with epirubicin
- What this could lead to
- If successful, this combination could shrink tumors enough to allow surgical removal, potentially improving disease control and survival for a rare cancer with few options.
- What could go wrong
- This is a small, early-phase trial (40 people) with no control group. The drugs may cause side effects like nerve damage or heart toxicity, and the response rate may be too low to enable surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye & ENT Hospital of Fudan University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors
- Rare sinus cancer study aims to clarify treatment outcomes